Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is a real-world study to observe the role of adjuvant radiotherapy in locally advanced recurrent high-risk thyroid cancer. The study included thyroid cancer that requires adjuvant radiotherapy to increase local control rate, excluding undifferentiated cancer. Local-regional recurrence free survival is the primary endpoint of the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Adjuvant radiotherapy | Locally advanced recurrent high-risk thyroid cancer patients who had adjuvant radiotherapy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| adjuvant radiotherapy | Radiation | The patients would receive external radiation therapy within 6 weeks after surgery, using intensity-modulated radiation therapy (IMRT) or volume modulated radiation therapy (VMAT) techniques. 6MV-X-ray irradiation. Conventional segmented irradiation is used, once a day, five times a week, with a segmented dose of 2Gy per dose. |
| Measure | Description | Time Frame |
|---|---|---|
| LRRFS | Local-regional Recurrence Free Survival | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| DCR | Disease Control Rate | 5 years |
| PFS | Progression Free Survival | 5 years |
Not provided
Inclusion Criteria:
Patients voluntarily join this study and sign an informed consent form;
Age: ≥ 14 years old,<80 years old, male or female not limited;
Thyroid cancer diagnosed by histopathology, including differentiated thyroid cancer, medullary carcinoma, poorly differentiated carcinoma, etc;
High risk of local late recurrence, meeting any of the following criteria:
The main organ functions are normal;
Good compliance and cooperation with follow-up.
Exclusion Criteria:
Not provided
Not provided
Patients with high recurrence risk locally advanced thyroid cancer
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Naisi Huang | Contact | 86-021-64175590 | 67816 | huangnsisi@fduan.edu.cn |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fudan University Shanghai Cancer Center | Recruiting | Shanghai | 200032 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D013964 | Thyroid Neoplasms |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D006258 | Head and Neck Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D018714 | Radiotherapy, Adjuvant |
| ID | Term |
|---|---|
| D003131 | Combined Modality Therapy |
| D013812 | Therapeutics |
| D011878 | Radiotherapy |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| OS |
Overall Survival |
| 5 years |
| AE | Adverse Events | 5 years |
| QoL | Quality of Life | 5 years |
| D004700 |
| Endocrine System Diseases |
| D013959 | Thyroid Diseases |